Enantioselective HPLC-UV method for determination of eslicarbazepine acetate (BIA 2-093) and its metabolites in human plasma

Biomedical Chromatography

Volumn 21, Issue 11, 2007, Pages 1127-1134

  Alves, Gilberto ^a   Figueiredo, Isabel ^a   Castel Branco, Margarida ^a   Loureiro, Ana ^b   Fortuna, Ana ^a   Falcão, Amílcar ^a   Caramona, Margarida ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

Author keywords

Bioanalytical method validation; Enantioselective HPLC UV method; Eslicarbazepine acetate (BIA 2 093); Human plasma; Oxcarbazepine

Indexed keywords

CLINICAL RESEARCH; ENANTIOSELECTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PATIENT MONITORING; PATIENT TREATMENT; PHASE SEPARATION; PLASMA (HUMAN);

BIOANALYTICAL METHOD VALIDATION; BIOANALYTICAL METHODS; CENTRAL NERVOUS SYSTEMS; ENANTIOSELECTIVE HPLC; ENANTIOSELECTIVE HPLC-UV METHOD; ESLICARBAZEPINE ACETATE (BIA 2-093); HPLC-UV; HUMAN PLASMAS; METHOD VALIDATIONS; OXCARBAZEPINE;

METABOLITES;

ANTICONVULSIVE AGENT; BETA CYCLODEXTRIN; DRUG METABOLITE; ESLICARBAZEPINE ACETATE; LICARBAZEPINE; METHANOL; OXCARBAZEPINE; UNCLASSIFIED DRUG; WATER;

ARTICLE; CALIBRATION; CHIRALITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; DRUG RESEARCH; DRUG STABILITY; DRUG STRUCTURE; ENANTIOMER; ENANTIOSELECTIVITY; FLOW RATE; LINEAR SYSTEM; QUANTITATIVE ANALYSIS; RELIABILITY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOLID PHASE EXTRACTION; TEMPERATURE MEASUREMENT; ULTRAVIOLET SPECTROSCOPY; VALIDATION STUDY;

EID: 36749058390     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.858     Document Type: Article

References (42)

1. Almeida AM, Castel-Branco MM and Falcão AC. Linear regression for calibration lines revisited: weighting schemes for bioanalytical methods. Journal of Chromatography B 2002; 774: 215-222.
2. Almeida L and Soares-da-Silva P. Safety, Tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. Journal of Clinical Pharmacology 2004; 44: 906-918.
3. Almeida L and Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics 2007; 4: 88-96.
4. Almeida L, Falcão A, Maia J, Mazur D, Gellert M and Soares-da-Silva P. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. Journal of Clinical Pharmacology 2005; 45: 1062-1066.
5. Arroyo S and Kramer G. Treating Epilepsy in the Elderly: Safety Considerations. Drug Safety 2001; 24: 991-1015.
6. Bazil CW and Pedley TA. Advances in medical treatment of epilepsy. Annual Review of Medicine 1998; 49: 135-162.
7. Benes J, Parada A, Figueiredo AA, Alves PC, Freitas AP, Learmonth DA, Cunha RA, Garrett J and Soares-da-Silva P. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5h-dibenz[b,flazepine-5-carboxamide derivatives. Journal of Medicinal Chemistry 1999; 42: 2582-2587.
8. Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opinion on Investigational Drugs 2006; 15: 637-647.
9. Camel V. Solid phase extraction of trace elements. Spectrochimica Acta Part B 2003; 58: 1177-1233.
10. Coppola G. Treatment of partial seizures in childhood: an overview. CNS Drugs 2004; 18: 133-156.
11. Deckers CLP, Genton P, Sills GJ and Schmidt D. Current limitations of antiepileptic drug therapy: a conference review. Epilepsy Research 2003; 53: 1-17.
12. Duncan JS. The promise of new antiepileptic drugs. British Journal of Clinical Pharmacology 2002; 53: 123-131.
13. Elyas AA, Goldberg VD and Patsalos PN. Simple and rapid microanalytical high-performance liquid chromatographic technique for the assay of oxcarbazepine and its primary active metabolite 10-hydroxycarbazepine. Journal of Chromatography 1990 528: 473-479.
14. Flesch G. Overview of the clinical pharmacokinetics of oxcarbazepine. Clinical Drug Investigation 2004; 24: 185-203.
15. Flesch G, Francotte E, Hell F and Degen PH. Determination of the R-(-) and S-(+) enantiomers of the monohydroxylated metabolite of oxcarbazepine in human plasma by enantioselective high-performance liquid chromatography. Journal of Chromatography 1992; 581: 147-151.
16. Franceschi L and Furlanut M. A simple method to monitor plasma concentrations of oxcarbazepine, carbamazepine, their main metabolites and lamotrigine in epileptic patients. Pharmacological Research 2005; 51: 297-302.
17. Hainzl D, Parada A and Soares-da-Silva P. Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine. Epilepsy Research 2001; 44: 197-206.
18. Janchawee B, Keawpradub N, Chittrakarn S, Prasettho S, Wararatananurak P and Sawangjareon K. A high-performance liquid chromatographic method for determination of mitragynine in serum and its application to a pharmacokinetic study in rats. Biomedical Chromatography 2007; 21: 176-183.
19. Jarrar RG and Buchhalter JR. Therapeutics in pediatric epilepsy, part 1: the new antiepileptic drugs and the ketogenic diet. Mayo Clinic Proceedings 2003; 78: 359-370.
20. Johannessen SI, Battino D, Berry DJ, Bialer M, Kramer G, Tomson T and Patsalos PN. Therapeutic Drug Monitoring of the Newer Antiepileptic Drugs. Therapeutic Drug Monitoring 2003; 25: 347-363.
21. Lanckmans K, Clinckers R, Eeckhaut AV, Sarre S, Smolders I and Michotte Y. Use of microbore LC-MS/MS for the quantification of oxcarbazepine and its active metabolite in rat brain microdialysis samples. Journal of Chromatography B 2006; 831: 205-212.
22. Levert H, Odou P and Robert H. Simultaneous determination of four antiepileptic drugs in serum by high-performance liquid chromatography. Biomedical Chromatography 2002; 16: 19-24.
23. Mandrioli R, Ghedini N, Albani F, Kenndler E and Raggi MA. Liquid chromatographic determination of oxcarbazepine and its metabolites in plasma of epileptic patients after solid-phase extraction. Journal of Chromatography B 2003; 783: 253-263.
24. May TW, Korn-Merker E and Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clinical Pharmacokinetics 2003; 42: 1023-1042.
25. Menge GP, Dubois JP and Bauer G. Simultaneous determination of carbamazepine, oxcarbazepine and their main metabolites in plasma by liquid chromatography. Journal of Chromatography 1987; 414: 477-483.
26. Misl'anová C and Hutta M. Role of biological matrices during the analysis of chiral drugs by liquid chromatography. Journal of Chromatography B 2003; 797: 91-109.
27. Myllynen P, Pienimaki P, Raunio H and Vahakangas K. Microsomal metabolism of carbamazepine and oxcarbazepine in liver and placenta. Human & Experimental Toxicology 1998; 17: 668-676.
28. Neels HM, Sierens AC, Naelaerts K, Scharpé SL, Hatfield GM and Lambert WE. Therapeutic drug monitoring of old and newer antiepileptic drugs. Clinical Chemistry and Laboratory Medicine 2004; 42: 1228-1255.
29. Noirfalise A and Collinge A. Quantitative determination of oxcarbazepine. Journal of Chromatography 1983; 274: 417-420.
30. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clinical Pharmacokinetics 2000; 38: 191-204.
31. Peters FT and Maurer HH. Bioanalytical method validation and its implications for forensic and clinical toxicology - a review. Accreditation and Quality Assurance 2002; 7: 441-449.
32. Pichini S, Altieri I, Passa AR, Zuccaro P and Pacifi R. Stereoselective bioanalysis of oxcarbazepine and the enantiomers of its metabolites by high-performance liquid chromatography. Journal of Liquid Chromatography 1995; 18: 1533-1541.
33. Pienimaki P, Fuchs S, Isojarvi J and Vahakangas K. Improved detection and determination of carbamazepine and oxcarbazepine and their metabolites by high-performance liquid chromatography. Journal of Chromatography B 1995; 673: 97-105.
34. Reinikainen KJ, Keranen T, Halonen T, Komulainen H and Riekkinen PJ. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Reseach 1987; 1: 284-289.
35. Rouan MC, Decherf M, Le Clanche V, Lecaillon JB and Godbillon J. Automated microanalysis of oxcarbazepine and its monohydroxy and transdiol metabolites in plasma by liquid chromatography. Journal of Chromatography B 1994; 658: 167-172.
36. Schachter SC. Oxcarbazepine: current status and clinical applications. Expert Opinion on Investigational Drugs 1999; 8: 1103-1112.
37. Shah VP, Midha KK, Findlay JWA, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT and Yacobi A. Bioanalytical method validation - a revisit with a decade of progress. Pharmaceutical Research 2000; 17: 1551-1557.
38. Soriano T, Jurado C, Menéndez M and Repetto M. Improved solid-phase extraction method for systematic toxicological analysis in biological fluids. Journal of Analytical Toxicology 2001; 25: 137-143.
39. Souppart C, Decherf M, Humbert H and Maurer G. Development of a high throughput 96-well plate sample preparation method for the determination of trileptal (oxcarbazepine) and its metabolites in human plasma. Journal of Chromatography B 2001; 762: 9-15.
40. Velpandian T, Mathur R, Agarwal NK, Arora B, Kumar L and Gupta SK. Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. Journal of Chromatography B 2004; 804: 431-434.
41. Volosov A, Xiaodong S, Perucca E, Yagen B, Sintov A and Bialer M. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clinical Pharmacology & Therapeutics 1999; 66: 547-553.
42. Volosov A, Bialer M, Xiaodong S, Perucca E, Sintov A and Yagen B. Simultaneous stereoselective high-performance liquid chromatographic determination of 10-hydroxycarbazepine and its metabolite carbamazepine-10,11-trans-dihydrodiol in human urine. Journal of Chromatography B 2000; 738: 419-425.